DOCSLIB.ORG

Complement Factor H: Solution Structures and Interactions with Ligands

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Complement Factor H: Solution Structures and Interactions with Ligands Complement Factor H: Solution Structures and Interactions with Ligands Thesis Presented for the Degree of Doctor of Philosphy by Azubuike Ifeanyi Okemefuna Institute of Structural and Molecular Biology, University College London June 2009 I, Azubuike Ifeanyi Okemefuna, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Abstract Factor H (FH) is a plasma glycoprotein that plays a central role in regulating the alternative pathway of complement. It is composed of 20 short complement regulator (SCR) domains. The SCR-1/5 fragment is required for decay acceleration and cofactor activity, while the SCR-16/20 fragment possesses binding sites for complement C3d and host cell-surface polyanionic ligands. C3d is a 35-kDa fragment of C3b, the activated form of the central complement protein C3. C- reactive protein (CRP) is an acute-phase reactant that activates complement through the classical pathway but inhibits the alternative pathway. In this thesis, X-ray scattering, analytical ultracentrifugation (AUC) and constrained modelling were used to determine solution structures for the SCR-1/5 and SCR-16/20 fragments, as well as for intact FH. Surface plasmon resonance (SPR) was used in conjunction with these methods to investigate the interactions of FH with C3d and CRP in the fluid and solid phases. Structural studies revealed that at physiological concentrations, SCR-1/5 is monomeric and SCR-16/20 exists in a weak monomer-dimer equilibrium. In the best-fit models, both FH fragments adopt a partially folded-back orientation in solution, and the SCR-16/20 dimer is formed by association of two SCR-20 domains. FH exists in a partially folded-back orientation in solution and forms oligomers. Here, these FH oligomers were shown to exist under different buffer conditions of NaCl concentration and pH, and these two factors also influence the conformation of FH. New, significantly improved molecular structures showed that FH orientation is maintained by short-to-middle distance interdomain interactions. There was no evidence of long distance interactions between the N- and C-terminals of FH. Studies on the interaction of FH with C3d identified a number of multimeric complexes formed between C3d and both SCR-16/20 and native FH. Binding to C3d did not significantly increase the overall length of FH, and this interaction is NaCl concentration-dependent. CRP, another ligand of FH, is known to exist physiologically as a pentamer. Here, CRP is shown to exist in a pentamer-decamer equilibrium under physiological buffer conditions. This equilibrium is NaCl concentration dependent and occurs in both fluid and solid phases. SPR binding studies showed that interaction with CRP inhibits FH oligomerisation, and further identified a novel CRP-binding site within SCR-16/20 of FH. Thus ionic strength- dependence may be a general feature of FH interaction with its ligands. These results provide insight into the complement regulatory activity of FH. i Acknowledgements I would like to thank my supervisor Professor S. J. Perkins for his guidance and encouragement throughout the period of my work with him. I am also grateful to the other two members of my thesis committee, Dr. Andrew Martin and Professor Martin Crompton, for their advice and support. I would like to thank my collaborators, including Professor David L. Gordon, Dr Rebecca Ormsby, Dr. Tania Sadlon and Ms. Kim Griggs for their expertise and for supplying the proteins and expression systems used in my studies. I am very grateful to the UCL graduate school and Overseas Research Fund for a postgraduate scholarship. My thanks also go to Mr. Jayesh Gor for his invaluable help with experiments and lab work. I thank Dr. Patricia Furtado for her helpful and gentle advice, and my colleagues at UCL for their untiring help, understanding and patience. And lastly, to my parents and family - thank you all for believing. ii Contents Page Chapter One The Complement Cascade 1 1.1 Introduction to complement 2 1.2 Complement activation 3 1.2.1 C3 in complement activation 5 1.2.2 The classical pathway 7 1.2.3 The alternative pathway 9 1.2.4 The lectin pathway 11 1.2.5 The membrane attack complex 12 1.3 Regulation of complement activation 12 1.4 Biosynthesis of complement proteins 16 1.5 Complement in disease 16 Chapter Two Factor H of Complement 19 2.1 Factor H expression and biosynthesis 20 2.1.1 The Factor H gene family 20 2.1.2 Factor H expression and sequence 20 2.1.3 Biosynthesis of Factor H 21 2.2 Structure of Factor H 21 2.2.1 The SCR domain structure 21 2.2.2 Structures of Factor H SCR domains 24 2.2.3 Factor H inter-domain arrangements 27 2.3 Function of Factor H in complement 28 2.3.1 Regulation of complement activation 28 2.3.2 Factor H binding to C3b 30 2.3.3 Factor H binding to CRP 31 2.3.3.1 Introduction to human CRP 31 2.3.3.2 Factor H interaction with CRP as a means of complement 33 regulation 2.3.3.3 The role of the interaction between Factor H 34 and CRP in the molecular mechanism of age-related macular degeneration iii 2.3.4 Factor H binding to other ligands 35 2.4 Factor H mutations and disease 35 Chapter Three Protein Structure and Interaction Measurement 38 3.1 Introduction to protein structure determination 39 3.2 Analytical ultracentrifugation 41 3.2.1 Introduction to the analytical ultracentrifuge 41 3.2.2 Uses of analytical ultracentrifugation 42 3.2.3. Theory of sedimentation 42 3.2.4. Instrumentation 46 3.2.4.1. The rotor 46 3.2.4.2. The cells 46 3.2.4.3. Absorbance optics 48 3.2.4.4. Interference optics 48 3.2.5. Applications of analytical ultracentrifugation 50 3.2.5.1. Sedimentation velocity 50 3.2.5.2. Sedimentation equilibrium 51 3.2.5.3 Analytical ultracentrifugation data analyses 51 3.3 Solution scattering 55 3.3.1 Introduction to solution scattering 55 3.3.2 Types of solution scattering 56 3.3.3 Theory of solution scattering 56 3.3.4 Properties of X-ray scattering experiments 58 3.3.5 Instrumentation 61 3.3.6 X-ray sources 61 3.3.7 Data interpretation 65 3.3.7.1 Guinier analyses 65 3.3.7.2 Distance distribution function analyses 66 3.4 Biomolecular modelling 69 3.4.1 Scattering curve modelling 69 3.4.1.1 Analysis of protein composition 69 3.4.1.2 Creating atomic models 70 3.4.1.3 Molecular model searches 70 iv 3.4.1.4 Sphere modeling 71 3.4.1.5 Debye scattering curve calculation 72 3.4.2 Identification of best-fit models 72 3.4.3 Calculation of hydrodynamic properties 73 3.5 Introduction to protein interaction measurement 73 3.5.1 Surface plasmon resonance 75 3.5.2 Experiments on the Biacore X100 77 3.5.3 Applications of Biacore systems 79 3.5.3.1 Binding analyses 80 3.5.3.2 Equilibrium analyses 80 3.5.3.3 Concentration assays 81 Chapter Four The Regulatory SCR-1/5 and Cell-surface-binding SCR-16/20 87 Fragments of Factor H Reveal Partially Folded-back Solution Structures and Different Self-associative Properties 4.1 Introduction 88 4.2 Results and Discussion 89 4.2.1 X-ray scattering data for SCR-1/5 and SCR-16/20 89 4.2.2 Analytical ultracentrifugation data for SCR-1/5 and SCR-16/20 97 4.2.3 Constrained scattering modelling of SCR-1/5 and 105 monomeric SCR-16/20 4.2.4 Trial models for dimeric SCR-16/20 114 4.3 Conclusions 117 4.4 Materials and Methods 125 4.4.1 Expression and preparation of SCR-1/5 and SCR-16/20 125 4.4.2 X-ray scattering data collection and analysis 126 4.4.3. Sedimentation velocity and equilibrium data 128 for SCR-1/5 and SCR-16/20 4.4.4. Modelling of the SCR-1/5 and SCR-16/20 solution structures 129 4.4.5 Debye scattering and sedimentation coefficient modelling 130 4.4.6 Protein data bank accession number 131 v Chapter Five Electrostatic Interactions Contribute to the Folded-back 132 Conformation of Wild-type Human Factor H 5.1 Introduction 133 5.2 Results and Discussion 134 5.2.1 Analytical ultracentrifugation of Factor H 134 5.2.2 X-ray scattering data for Factor H 146 5.2.3 Constrained scattering modelling of monomeric Factor H 150 5.3 Conclusions 158 5.4 Materials and Methods 167 5.4.1 Purification of Factor H 167 5.4.2 Sedimentation velocity data for Factor H 169 5.4.3 X-ray scattering data collection and analysis 170 5.4.4 Modelling of the Factor H solution structures 171 5.4.5 Debye scattering and sedimentation coefficient modelling 172 5.4.6 Protein Data Bank accession number 173 Chapter Six Multimeric Interactions Between Complement Factor H and its C3d 174 Ligand Provide New Insight on Complement Regulation 6.1 Introduction 175 6.2 Results and Discussion 176 6.2.1 Solution structural data for the Factor H-C3d complex 176 6.2.2 Analytical ultracentrifugation of C3d 179 6.2.2.1 Sedimentation velocity data for C3d 179 6.2.2.2 Sedimentation equilibrium data for C3d 181 6.2.3 Analytical ultracentrifugation of the SCR-16/20 and Factor H 183 complexes with C3d 6.2.3.1 Sedimentation velocity data for the SCR-16/20 complex 183 with C3d 6.2.3.2 Sedimentation velocity data for the complex 188 of native Factor H with C3d 6.2.4 Surface plasmon resonance studies of the complexes of Factor H 190 and SCR-16/20 with C3d vi 6.2.5 X-ray scattering data of the SCR-16/20 complex with C3d 197 6.2.6 Molecular modelling of SCR-16/20 complexes with C3d 201 6.3 Conclusions 205 6.4 Materials and methods 211 6.4.1 Protein expression and purification 211 6.4.2 Analytical ultracentrifugation data and analysis 215 6.4.2.1 Sedimentation velocity data for C3d and its complexes 215 with Factor H and SCR-16/20 6.4.2.2 Sedimentation equilibrium data for C3d 216 6.4.3
Load more

Recommended publications
  • Regulation of the Complement System by Pentraxins
    REVIEW published: 02 August 2019 doi: 10.3389/fimmu.2019.01750 Regulation of the Complement System by Pentraxins Karita Haapasalo 1 and Seppo Meri 1,2,3* 1 Department of Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland, 2 HUSLAB, Helsinki University Hospital, Helsinki, Finland, 3 Department of Biomedical Sciences, Humanitas University, Milan, Italy The functions of pentraxins, like C-reactive protein (CRP), serum amyloid protein P (SAP) and pentraxin-3 (PTX3), are to coordinate spatially and temporally targeted clearance of injured tissue components, to protect against infections and to regulate related inflammation together with the complement system. For this, pentraxins have a dual relationship with the complement system. Initially, after a focused binding to their targets, e.g., exposed phospholipids or cholesterol in the injured tissue area, or microbial components, the pentraxins activate complement by binding its first component C1q. However, the emerging inflammation needs to be limited to the target area. Therefore, pentraxins inhibit complement at the C3b stage to prevent excessive damage. The complement inhibitory functions of pentraxins are based on their ability to interact with complement inhibitors C4bp or factor H (FH). C4bp binds to SAP, while FH binds to Edited by: both CRP and PTX3. FH promotes opsonophagocytosis through inactivation of C3b to Barbara Bottazzi, Milan University, Italy iC3b, and inhibits AP activity thus preventing formation of the C5a anaphylatoxin and the Reviewed by: complement membrane attack complex (MAC). Monitoring CRP levels gives important Livija Deban, clinical information about the extent of tissue damage and severity of infections. CRP is a Prokarium, United Kingdom valuable marker for distinguishing bacterial infections from viral infections.
    [Show full text]
  • Nephrology Clinical Laboratory Research Compendium
    Nephrology Clinical Laboratory Research Compendium The Nephrology Clinical Laboratory at Cincinnati Children’s Hospital Medical Center has expanded its clinical testing menu to now offer testing on a research basis. The CAP and CLIA certified laboratory operates under Good Clinical Laboratory Practice principles to ensure testing can be used to support findings of clinical trials. CONTACT US Our state of the art laboratory offers a broad testing menu to support research and pharmaceutical projects. We have the capability to perform traditional For more information on research or ELISA’S, multiplexing using the MSD Meso discovery, luminex magnetic bead clinical testing, please contact us at: assays, nephelometry and clinical chemistry. Phone: 513-636-4530 [email protected] The Nephrology Clinical Laboratory Research Compendium offers clinical chemistry, therapeutic drug monitoring, immunology, complement quantitation, www.cincinnatichildrens.org function and activation, specialty proteins and testing for various forms of thrombotic microangiopathies. COMPLEMENT SPECIALTY TESTING Autoantibody Testing Complement Components • Factor H Autoantibody (Quantitative) • C3 Nephritic Factor • C1 inhibitor (quantitative) • Factor B Autoantibody • C1q • C2 Functional Testing • C3 • CH50 • C4 • Alternative Pathway Functional Assay • C5 • MBL Pathway Functional Assay • C6 • C1 inhibitor Functional Assay • C7 • C8 Complement Activation Fragments • C9 • Complement Bb • Factor B • Complement Ba • Factor H • C3a • Factor I • C3c • Properdin • C3d
    [Show full text]
  • WO 2016/147053 Al 22 September 2016 (22.09.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/147053 Al 22 September 2016 (22.09.2016) P O P C T (51) International Patent Classification: (71) Applicant: RESVERLOGIX CORP. [CA/CA]; 300, A61K 31/551 (2006.01) A61P 37/02 (2006.01) 4820 Richard Road Sw, Calgary, AB, T3E 6L1 (CA). A61K 31/517 (2006.01) C07D 239/91 (2006.01) (72) Inventors: WASIAK, Sylwia; 431 Whispering Water (21) International Application Number: Trail, Calgary, AB, T3Z 3V1 (CA). KULIKOWSKI, PCT/IB20 16/000443 Ewelina, B.; 31100 Swift Creek Terrace, Calgary, AB, T3Z 0B7 (CA). HALLIDAY, Christopher, R.A.; 403 (22) International Filing Date: 138-18th Avenue SE, Calgary, AB, T2G 5P9 (CA). GIL- 10 March 2016 (10.03.2016) HAM, Dean; 249 Scenic View Close NW, Calgary, AB, (25) Filing Language: English T3L 1Y5 (CA). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 62/132,572 13 March 2015 (13.03.2015) US BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 62/264,768 8 December 2015 (08. 12.2015) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, [Continued on nextpage] (54) Title: COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES (57) Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders as sociated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)- 5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    [Show full text]
  • Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders
    Hindawi Publishing Corporation Autism Research and Treatment Volume 2012, Article ID 868576, 6 pages doi:10.1155/2012/868576 Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders Naghi Momeni,1 Lars Brudin,2 Fatemeh Behnia,3 Berit Nordstrom,¨ 4 Ali Yosefi-Oudarji,5 Bengt Sivberg,4 Mohammad T. Joghataei,5 and Bengt L. Persson1 1 School of Natural Sciences, Linnaeus University, 39182 Kalmar, Sweden 2 Department of Clinical Physiology, Kalmar County Hospital, 39185 Kalmar, Sweden 3 Department of Occupational Therapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 4 Department of Health Sciences, Autism Research, Faculty of Medicine, Lund University, Box 157, 22100 Lund, Sweden 5 Cellular and Molecular Research Centre, Tehran University of Medical Sciences (TUMS), Tehran, Iran Correspondence should be addressed to Bengt Sivberg, [email protected] Received 17 June 2011; Revised 22 August 2011; Accepted 22 August 2011 Academic Editor: Judy Van de Water Copyright © 2012 Naghi Momeni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Autism spectrum disorders (ASDs) are neurodevelopmental and behavioural syndromes affecting social orientation, behaviour, and communication that can be classified as developmental disorders. ASD is also associated with immune system abnormality. Im- mune system abnormalities may be caused partly by complement system factor I deficiency. Complement factor I is a serine pro- tease present in human plasma that is involved in the degradation of complement protein C3b, which is a major opsonin of the complement system.
    [Show full text]
  • Advances in Hematology
    ADVANCES IN HEMATOLOGY Current Developments in the Management of Hematologic Disorders Hematology Section Editor: Craig M. Kessler, MD Atypical Hemolytic Uremic Syndrome: The Role of Complement Pathway Gene Mutation Analysis Ilene C. Weitz, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Los Angeles, California H&O What causes atypical hemolytic uremic H&O Which mutations in complement alternative syndrome (aHUS)? pathway genes are linked to aHUS? IW We think that most people with aHUS have problems IW Multiple genetic mutations have been linked to with regulation of complement. As a result of excess com- aHUS, especially those involved in the complement plement, endothelial and organ damage occur. We know alternative pathway. These include mutations in comple- that mutations in the genes of complement regulatory pro- ment factor H, complement factor I, membrane cofactor teins are associated with aHUS. In addition, factors other protein, complement factor B, and C3 nephritic factor. than underlying mutations may play a role in increasing Mutations may cause the protein to be normal but low in activation and the expression of the clinical syndrome. quantity, or normal in quantity but abnormal in function; the degree of the abnormality may depend on whether the H&O How is the complement system activated patient is heterozygous or homozygous. and regulated? In addition, other factors such as thrombomodulin have been described that work through other enzymes. IW The complement system is a part of the innate Thrombomodulin is involved in complement regulation immune system that is necessary for fighting infections by activating thrombin activatable fibrinolytic inhibitor and aberrant immunologic stimuli.
    [Show full text]
  • 367.Full.Pdf
    Human Complement Factor I Does Not Require Cofactors for Cleavage of Synthetic Substrates This information is current as Stefanos A. Tsiftsoglou and Robert B. Sim of October 2, 2021. J Immunol 2004; 173:367-375; ; doi: 10.4049/jimmunol.173.1.367 http://www.jimmunol.org/content/173/1/367 Downloaded from References This article cites 41 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/173/1/367.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human Complement Factor I Does Not Require Cofactors for Cleavage of Synthetic Substrates1 Stefanos A. Tsiftsoglou2 and Robert B. Sim Complement factor I (fI) plays a major role in the regulation of the complement system. It circulates in an active form and has very restricted specificity, cleaving only C3b or C4b in the presence of a cofactor such as factor H (fH), complement receptor type 1, membrane cofactor protein, or C4-binding protein.
    [Show full text]
  • By Map44 Pathway Activation in a Manner Inhibitable Pattern
    Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable This information is current as by MAp44 of September 28, 2021. Søren E. Degn, Lisbeth Jensen, Tomasz Olszowski, Jens C. Jensenius and Steffen Thiel J Immunol 2013; 191:1334-1345; Prepublished online 19 June 2013; Downloaded from doi: 10.4049/jimmunol.1300780 http://www.jimmunol.org/content/191/3/1334 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/06/19/jimmunol.130078 Material 0.DC1 References This article cites 43 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/191/3/1334.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable by MAp44 Søren E.
    [Show full text]
  • Crystal Structure of Prethrombin-1
    Crystal structure of prethrombin-1 Zhiwei Chen, Leslie A. Pelc, and Enrico Di Cera1 Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO 63104 Edited by Robert M. Stroud, University of California, San Francisco, CA, and approved September 24, 2010 (received for review July 14, 2010) Prothrombin is the zymogen precursor of the clotting enzyme thrombin, which is generated by two sequential cleavages at R271 and R320 by the prothrombinase complex. The structure of prothrombin is currently unknown. Prethrombin-1 differs from pro- thrombin for the absence of 155 residues in the N-terminal domain and is composed of a single polypeptide chain containing fragment 2 (residues 156–271), A chain (residues 272–320), and B chain (re- sidues 321–579). The X-ray crystal structure of prethrombin-1 solved at 2.2-Å resolution shows an overall conformation signifi- cantly different (rmsd ¼ 3.6 Å) from that of its active form meizo- thrombin desF1 carrying a cleavage at R320. Fragment 2 is rotated around the y axis by 29° and makes only few contacts with the B chain. In the B chain, the oxyanion hole is disrupted due to absence of the I16-D194 ion pair and the Naþ binding site and adjacent primary specificity pocket are highly perturbed. A remarkable feature of the structure is that the autolysis loop assumes a helical conformation enabling W148 and W215, located 17 Å apart in mei- zothrombin desF1, to come within 3.3 Å of each other and comple- tely occlude access to the active site.
    [Show full text]
  • O) 2 Platelets Mediated by Properdin and C3(H Complement Activation on Stimulated Identification of a Novel Mode Of
    Identification of a Novel Mode of Complement Activation on Stimulated Platelets Mediated by Properdin and C3(H2 O) This information is current as of October 1, 2021. Gurpanna Saggu, Claudio Cortes, Heather N. Emch, Galia Ramirez, Randall G. Worth and Viviana P. Ferreira J Immunol 2013; 190:6457-6467; Prepublished online 15 May 2013; doi: 10.4049/jimmunol.1300610 Downloaded from http://www.jimmunol.org/content/190/12/6457 Supplementary http://www.jimmunol.org/content/suppl/2013/05/17/jimmunol.130061 Material 0.DC1 http://www.jimmunol.org/ References This article cites 72 articles, 37 of which you can access for free at: http://www.jimmunol.org/content/190/12/6457.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 1, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Identification of a Novel Mode of Complement Activation on Stimulated Platelets Mediated by Properdin and C3(H2O) Gurpanna Saggu,*,1 Claudio Cortes,*,†,1 Heather N.
    [Show full text]
  • Factor B, the Complement Alternative Pathway Serine Proteinase, Is a Major Constitutive Protein Synthesized and Secreted by Resident and Elicited Mouse Macrophages
    FACTOR B, THE COMPLEMENT ALTERNATIVE PATHWAY SERINE PROTEINASE, IS A MAJOR CONSTITUTIVE PROTEIN SYNTHESIZED AND SECRETED BY RESIDENT AND ELICITED MOUSE MACROPHAGES BY JOHN S. SUNDSMO, JENNIE R. CHIN,* RUTH A. PAPIN, DARYL S. FAIR, AND ZENA WERB* From the Department of Molecular Immunology, Scripps Clinic and Research Foundation, La Jolla, California 92037; and the *Laboratory of Radiobiology and Environmental Health, and Department of Anatomy, University of California, San Francisco, California 94143 Mononuclear phagocytes have been increasingly recognized as a source of many of the complement proteins (1, 2). Activities constituting the intact com- plement alternative pathway in serum (factor B, factor D, C3, and properdin) (3-8), as well as the regulatory proteins, factors H and I (5, 8), are produced by mouse peritoneal macrophages and human peripheral blood monocytes. Factors C2 and C4 are also synthesized by mononuclear phagocytes (1, 2, 5, 9-11). Factor B, a glycoprotein of Mr ~0.3,000 that plays a central role in the alternative pathway of complement activation (12, 13), is closely associated with the immune response as a class III gene product of the major histocompatibility complex in mice (14, 15), guinea pigs (16), and humans (17). Activated factor B (Bb, Mr ~60,000) serves as a migration inhibiting factor (18), inducing macro- phage and monocyte spreading (19, 20) and possibly stimulating cytotoxic (21, 22) and bacteriocidai activities (23, 24) of monocytes in vitro. The hemolytic activity of factor B produced by resident mouse peritoneal macrophages (3, 6) increases linearly during 72-96 h in culture, and its synthesis is regulated by lipopolysaccharide (LPS) 1 (24).
    [Show full text]
  • Proteomic Alterations of HDL in Youth with Type 1 Diabetes and Their Associations with Glycemic Control: a Case-Control Study Evgenia Gourgari Georgetown University
    University of Kentucky UKnowledge Saha Cardiovascular Research Center Faculty Cardiovascular Research Publications 3-28-2019 Proteomic Alterations of HDL in Youth with Type 1 Diabetes and their Associations with Glycemic Control: A Case-Control Study Evgenia Gourgari Georgetown University Junfeng Ma Georgetown University Martin P. Playford National Heart, Lung and Blood Institute Nehal N. Mehta National Heart, Lung and Blood Institute Radoslav Goldman Georgetown University See next page for additional authors Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/cvrc_facpub Part of the Cardiology Commons, and the Circulatory and Respiratory Physiology Commons Repository Citation Gourgari, Evgenia; Ma, Junfeng; Playford, Martin P.; Mehta, Nehal N.; Goldman, Radoslav; Remaley, Alan T.; and Gordon, Scott M., "Proteomic Alterations of HDL in Youth with Type 1 Diabetes and their Associations with Glycemic Control: A Case-Control Study" (2019). Saha Cardiovascular Research Center Faculty Publications. 40. https://uknowledge.uky.edu/cvrc_facpub/40 This Article is brought to you for free and open access by the Cardiovascular Research at UKnowledge. It has been accepted for inclusion in Saha Cardiovascular Research Center Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Authors Evgenia Gourgari, Junfeng Ma, Martin P. Playford, Nehal N. Mehta, Radoslav Goldman, Alan T. Remaley, and Scott M. Gordon Proteomic Alterations of HDL in Youth with Type 1 Diabetes and their Associations with Glycemic Control: A Case-Control Study Notes/Citation Information Published in Cardiovascular Diabetology, v.
    [Show full text]
  • Hemolytic Uremic Syndrome: a Factor H Mutation (E1172stop) Causes Defective Complement Control at the Surface of Endothelial Cells
    Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells Stefan Heinen,* Miha´ly Jo´zsi,* Andrea Hartmann,* Marina Noris,† Giuseppe Remuzzi,† Christine Skerka,* and Peter F. Zipfel*‡ *Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute, and ‡Faculty of Biology, Friedrich Schiller University, Jena, Germany; and †Mario Negri Institute for Pharmacological Research Villa Camozzi, Ranica, Bergamo, Italy Defective complement regulation results in hemolytic uremic syndrome (HUS), a disease that is characterized by microangi- opathy, thrombocytopenia, and acute renal failure and that causes endothelial cell damage. For characterization of how defective complement regulation relates to the pathophysiology, the role of the complement regulator factor H and also of a mutant factor H protein was studied on the surface of human umbilical vein endothelial cells. The mutant 145-kD factor H protein was purified to homogeneity, from plasma of a patient with HUS, who is heterozygous for a factor H gene mutation G3587T, which introduces a stop codon at position 1172. Functional analyses show that the lack of the most C-terminal domain short consensus repeats 20 severely affected recognition functions (i.e., binding to heparin, C3b, C3d, and the surface of endothelial cells). Wild-type factor H as well as the mutant protein formed dimers in solution as shown by cross-linking studies and mass spectroscopy. When assayed in fluid phase, the complement regulatory activity of the mutant protein was normal and comparable to wild-type factor H. However, on the surface of endothelial cells, the mutant factor H protein showed severely reduced regulatory activities and lacked protective functions.
    [Show full text]